Skip to main
OCS

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding AG is positioned to benefit significantly from its innovative pipeline, including OCS-01 for diabetic macular edema, OCS-02 for dry eye disease, and OCS-05 for acute optic neuritis and other neuro-ophthalmic disorders. The FDA's granting of Breakthrough Therapy Designation for OCS-05 highlights the critical unmet need in acute neuro-ophthalmic conditions, while OCS-01's successful outcomes in pivotal efficacy endpoints further substantiate the potential for substantial market success, with projected peak sales in AON and NAION reaching $1.2 billion and $623 million, respectively, by 2035. The company's strategic focus on treating underserved areas in ophthalmic diseases, coupled with a validated and diversified pipeline, underpins a favorable market outlook and enhanced growth prospects.

Bears say

Oculis Holding reported a net loss of CHF 16.9 million for the third quarter of 2025, indicating ongoing financial strain that raises concerns about the company's profitability. The high operating expenses associated with the continued late-stage development of its product portfolio add to the financial pressures, especially given the risks tied to clinical trial failures and intense competition within the biopharmaceutical industry. Additionally, the company's product candidates face challenges in market adoption due to existing effective treatments that deter early intervention, further complicating Oculis's path to successfully commercializing its innovative therapies.

OCS has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 7 analysts, OCS has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.